Hemab Therapeutics (COAG)

Hemab’s pipeline targets diseases such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. These conditions involve defects in platelets, clotting factors, or proteins that are essential to normal haemostasis. Because many of these disorders are rare, treatment options can be limited, burdensome, or primarily reactive rather than preventive. Hemab is developing medicines intended to reduce bleeding risk before events occur, which is an important distinction in the management of severe coagulation disorders.

The company’s lead programme is sutacimig, also known as HMB-001, a bispecific antibody being evaluated in clinical trials for prophylactic use in Glanzmann thrombasthenia and Factor VII deficiency. As a biologic therapy, sutacimig is designed to address specific mechanisms involved in clot formation, rather than simply replacing missing components in a conventional way.

Hemab has one operating segment, dedicated to research and development of therapeutics for bleeding disorders. Like other clinical-stage biotech companies, its investment profile is closely linked to trial progress, regulatory outcomes, funding needs, and the commercial potential of its drug candidates. The company does not represent a diversified pharmaceutical business; instead, it is a specialised developer seeking to build a portfolio in rare coagulation diseases.